Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platform

BMC Cancer

Technical Advance

Thomas Hankemeier¹  Jia Yu²  Junmei Cairns²  Liewei Wang²  Richard Weinshilboum²  Jos Joore³  Paul Vulto³  Chee Ping Ng³  Henriette L. Lanz³  Sebastiaan J. Trietsch³  Bart Kramer³  Anthony Saleh⁴ 

[1] Leiden University, Leiden, The Netherlands;Mayo Clinic, Rochester, Minnesota, USA;Mimetas BV, Leiden, The Netherlands;Mimetas BV, Leiden, The Netherlands;NIH, Bethesda, Maryland, USA;

关键词: Organ-on-a-chip;    Personalized medicine;    Triple negative;    P53 and BRCA1;   

DOI  :  10.1186/s12885-017-3709-3

 received in 2016-05-12, accepted in 2017-10-27,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundBreast cancer is the most common invasive cancer among women. Currently, there are only a few models used for therapy selection, and they are often poor predictors of therapeutic response or take months to set up and assay. In this report, we introduce a microfluidic OrganoPlate® platform for extracellular matrix (ECM) embedded tumor culture under perfusion as an initial study designed to investigate the feasibility of adapting this technology for therapy selection.MethodsThe triple negative breast cancer cell lines MDA-MB-453, MDA-MB-231 and HCC1937 were selected based on their different BRCA1 and P53 status, and were seeded in the platform. We evaluate seeding densities, ECM composition (Matrigel®, BME2rgf, collagen I) and biomechanical (perfusion vs static) conditions. We then exposed the cells to a series of anti-cancer drugs (paclitaxel, olaparib, cisplatin) and compared their responses to those in 2D cultures. Finally, we generated cisplatin dose responses in 3D cultures of breast cancer cells derived from 2 PDX models.ResultsThe microfluidic platform allows the simultaneous culture of 96 perfused micro tissues, using limited amounts of material, enabling drug screening of patient-derived material. 3D cell culture viability is improved by constant perfusion of the medium. Furthermore, the drug response of these triple negative breast cancer cells was attenuated by culture in 3D and differed from that observed in 2D substrates.ConclusionsWe have investigated the use of a high-throughput organ-on-a-chip platform to select therapies. Our results have raised the possibility to use this technology in personalized medicine to support selection of appropriate drugs and to predict response to therapy in a real time fashion.

【 授权许可】

CC BY   
© The Author(s). 2017